PRESS RELEASE · PRESS RELEASE · PRESS RELEASE
NEOVACS TO PRESENT THE PRECLINICAL RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4 / IL-13 KINOID
AT KEYSTONE CONGRESS:
“Origins of Allergic Disease: Microbial, Epithelial and Immune Interactions”
TAHOE CITY (CA), USA – March 24 - 27, 2019
Paris and Boston, March 21, 2019 – 07h30am CET - Neovacs (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the presentation of the preclinical results of its proof of concept in allergy with its new IL-4 / IL-13 Kinoid therapeutic vaccine, during the poster session at the upcoming Keystone allergy conference , taking place March 24 – 27, 2019, in Tahoe City, California, United States.
This work conducted in collaboration with a research team from the Institut Pasteur (Dr. Laurent Reber and Dr. Pierre Bruhns), showed in a representative allergic asthma model that a treatment with IL-4 / IL-13 Kinoid enhanced the production of polyclonal antibodies which neutralized the two targeted cytokines IL-4 and IL-13, both being development factors for allergic asthma, thus avoiding the occurrence of any symptoms.
About Keystone congress
Keystone Symposia will serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society. https://bit.ly/2JlEMwy
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 1 53 10 93 00
cmasson@neovacs.com
NEWCAP- Media
Annie-Florence Loyer
+33 1 44 71 00 12 / + 33 6 88 20 35 59
afloyer@newcap.fr
Léa Jacquin
+33 1 44 71 20 41 / +33 6 58 14 84 66
ljacquin@newcap.fr
ORPHEON FINANCE – Financial Communication and Investor Relations
James Palmer
+33 7 60 92 77 74
j.palmer@orpheonfinance.com
Attachment
